ABSTRACT
A study was conducted in São Paulo, Brazil, to compare azithromycin with thiamphenicol for the single-dose treatment of chancroid. In all, 54 men with chancroid were tested. The etiology was determined by clinical characterization and direct bacterioscopy with Gram staining. None of the patients had positive serology or dark-field examination indicating active infection with Treponema pallidum. Genital infections due to Neisseria gonorrhoeae and herpes simplex virus were excluded by polymerase chain reaction testing. For 54 patients with chancroid, cure rates with single-dose treatment were 73 percent with azithromycin and 89 percent with thiamphenicol. HIV seropositivity was found to be associated with treatment failure (p=0.001). The treatment failed in all HIV positive patients treated with azithromycin (p=0.002) and this drug should be avoided in these co-infected patients. In the view of the authors, thiamphenicol is the most indicated single-dose regimen for chancroid treatment.
Subject(s)
Humans , Male , AIDS-Related Opportunistic Infections/drug therapy , Anti-Bacterial Agents/administration & dosage , Azithromycin/administration & dosage , Chancroid/drug therapy , Thiamphenicol/administration & dosage , Cohort Studies , Prospective Studies , Treatment FailureABSTRACT
Thiamphenicol, an aminic derivate of hydrocarbilsulfonil propandiol, was used for the treatment of 1,171 chancroid bearing patients. Each patient was medicated with 5.0 g of granulated thiamphenicol, orally, in a single dose, and was reevaluated 3, 7 and 10 days after the treatment. Ten patients (0.89 percent) did not respond to the proposed treatment. 133 patients presented healed ulcers after 3 days of treatment, 976 patients healed chancres on the seventh day after the treatment, and 39 patients took 10 days to present healed chancres. The results of this study indicate that the rate of patients that were cured, the low incidence of side effects, and the practicality of administration make of thiamphenicol an excellent choice for the treatment of chancroid.
Subject(s)
Humans , Male , Adolescent , Adult , Middle Aged , Anti-Bacterial Agents/therapeutic use , Chancroid/drug therapy , Thiamphenicol/therapeutic use , Anti-Bacterial Agents/administration & dosage , Thiamphenicol/administration & dosage , Time Factors , Treatment OutcomeABSTRACT
Sexually transmitted diseases [STDs] are important public health problems. Recently WHO has recommended the syndromic approach for management of these diseases and the same has been adapted in the national STD control programme of Ministry of Health in Oman. This paper explains the advantages of syndromic approach and how it is integrated with preventive measures such as partner management, counselling and provision of condoms
Subject(s)
Humans , Sexually Transmitted Diseases, Bacterial/classification , Sexually Transmitted Diseases, Viral/classification , Syphilis/drug therapy , Gonorrhea/drug therapy , Urethritis/drug therapy , Herpes Genitalis/drug therapy , Condylomata Acuminata , Chancroid/drug therapy , Candidiasis/drug therapy , Trichomonas Infections , Sexually Transmitted Diseases , Disease Transmission, Infectious , Granuloma Inguinale , Molluscum ContagiosumABSTRACT
Este nuevo esquema de tratamiento es prometedor, dado que lo que se persigue en enfermedades de transmisión sexual es su control, con una dosis única de un medicamente (10). Esto contribuye a un mejor control epidemiológico de la enfermedad, dado que tiene una mejor aceptación y cumplimiento del tratamiento, curaciones rápidas y abaratamiento del costo por paciente tratado. Por otro lado, la tolerancia al tianfenicol es excelente y no tiene los efectos tóxicos que se le atribuye con frecuencia al cloramfenicol (8)
Subject(s)
Humans , Male , Thiamphenicol/therapeutic use , Chancroid/drug therapyABSTRACT
Os autores apresentam os resultados obtidos com o emprego do tianfenicol, utilizado por via oral e parenteral, em vários esquemas terapêuticos, portadores de blenorragia e cancro mole, analisando os resultados obtidos e considerando esquemas válidos em sua utilizaçäo
Subject(s)
Child , Adolescent , Adult , Humans , Male , Female , Chancroid/drug therapy , Thiamphenicol/therapeutic use , Drug Administration ScheduleABSTRACT
Os autores trataram 25 pacientes masculinos portadores de cancro venéreo simples con tianfenicol. O esquema indicado foi de 1,5g/dia fracionados em 3 doses de 500mg cada, durante 5 dias. Todos os pacientes evoluiram para a cura entre 4 e 8 dias após início do tratamento. Os efeitos colaterais foram esporádicos e de curta duraçäo; houve durante o tratamento dois casos de epigastralgia e um caso de cefaléia, näo tendo sido necessária a interrupçäo do tratamento